



## Metastatic Breast Cancer Treatment

For Advanced Breast Cancer Patients

**WEMPRA**<sup>TM</sup>  
(ixabepilone) for Injection

(ixabepilone) for Injection

**Wemp**ra the treatment  
**of** aggressive metastatic or locally  
advanced breast cancer no longer  
responding to currently  
**available chemotherapies.**



**WEMPRA Offers New Hope for Breast Cancer Treatment.**

WEMPRA (ixabepilone) is a semisynthetic analog of epothilone B indicated for the treatment of patients with metastatic or locally **advanced breast cancer.**

WEMPRA is indicated as monotherapy for the treatment of metastatic or locally **advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.**

WEMPRA is indicated in combination with capecitabine for the **treatment of patients with metastatic or locally advanced breast cancer** resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Anthracycline resistance is defined as progression while on therapy or within **6 months in the adjuvant setting or 3 months** in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant **setting or 4 months in the metastatic setting.**

Ixabepilone (INN; also known as azaepothilone B, codenamed BMS-247550) is an epothilone B analog

\*\*\* CANCER DRUG

For Advanced Breast Cancer Patients

**WEMPRA**<sup>TM</sup>  
(ixabepilone) for Injection